326,582 Shares in Harrow, Inc. (NASDAQ:HROW) Purchased by First Turn Management LLC

First Turn Management LLC purchased a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the third quarter, Holdings Channel reports. The firm purchased 326,582 shares of the company’s stock, valued at approximately $14,683,000. Harrow comprises about 2.3% of First Turn Management LLC’s holdings, making the stock its 22nd largest holding.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Harrow by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock valued at $24,208,000 after acquiring an additional 21,253 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Harrow in the 3rd quarter valued at approximately $534,000. Semanteon Capital Management LP purchased a new stake in shares of Harrow in the 3rd quarter valued at approximately $686,000. Private Capital Management LLC raised its stake in shares of Harrow by 7.8% in the 1st quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock valued at $39,854,000 after acquiring an additional 217,896 shares during the period. Finally, Apis Capital Advisors LLC purchased a new stake in shares of Harrow in the 2nd quarter valued at approximately $1,660,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Performance

Shares of NASDAQ:HROW opened at $37.97 on Tuesday. The firm has a fifty day moving average price of $47.92 and a 200 day moving average price of $32.58. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 1-year low of $8.72 and a 1-year high of $59.23.

Analysts Set New Price Targets

Several brokerages recently weighed in on HROW. B. Riley reaffirmed a “buy” rating and set a $50.00 target price on shares of Harrow in a research note on Thursday, August 29th. Craig Hallum upped their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, October 4th. Finally, Lake Street Capital upped their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.